Innoviva, Inc. INVA Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cost Reimbursement | $0— | $0-100% | $1.3M+62.5% | $800K+33.3% | $600K— | |
| Giapreza | $20.23M+3.5% | $19.55M+5.9% | $18.46M+6.5% | $17.33M-5.2% | $18.27M+13.7% | |
| Royalty | $55.17M+0.5% | $54.9M-8.3% | $59.9M-6.2% | $63.88M+10.5% | $57.81M-7.5% | |
| Xacduro | $18.07M-43.6% | $32.07M+34.7% | $23.81M+122% | $10.73M+37.9% | $7.78M+16.0% | |
| Percentage Of Royalty Payable On Net Sales by Product | ||||||
| Giapreza | 6%— | —— | —— | —— | 6%+4.5pp | |
| Royalty Expense by Product | ||||||
| Durlobactam | $0— | $0— | $0— | $0— | $0— | |
| Giapreza | $1.3M+8.3% | $1.2M+9.1% | $1.1M0.0% | $1.1M0.0% | $1.1M+22.2% | |
| Research And Development Expense by Product | ||||||
| External Services | $2.61M-13.4% | $3.01M+5.1% | $2.86M-57.8% | $6.78M+122% | $3.05M+12.7% | |
| Internal Expenses | $2.64M+70.4% | $1.55M+7.4% | $1.44M+19.8% | $1.2M-10.7% | $1.35M+40.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Innoviva, Inc. break its business down?
- Innoviva, Inc. (INVA) reports revenue by product across 4 parts — Cost Reimbursement, Giapreza, Royalty and Xacduro. Each is extracted from the segment footnotes and tracked over time.
- Where does Innoviva, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Innoviva, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
